FDA warns Forest Labs about Bystolic ads

Forest Laboratories Inc. received a warning letter from the FDA near the end of August for failure to show the risks of its high blood pressure medication, Bystolic, when promoting the drug to physicians.

The company ran an eight-page ad in a variety of medical journals favorably comparing the medication to other medications, but without enough research to support their claims. The advertisements omitted and minimized some of the risks associated with the drug--including cardiac failure and chest pain, as well as claimed the drug was superior for use in patients with obesity, diabetes and poor metabolism--without sufficient evidence to do so, according to the FDA. 

Share prices also dropped following legal claims on the Bystolic patent.

- catch the Forbes.com story
- read the Pharmalot blog post

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.